¿ËÈÕ£¬£¬£¬£¬£¬£¬£¬º¼ÖÝÊпÆÑ§ÊÖÒÕ¾ÖÐû²¼¡¶2025Äê¶Èº¼ÖÝÊÐÖØµã¿ÆÑÐÍýÏëÏîÄ¿£¨µÚÒ»Åú£©ÄâÁ¢ÏîÏîÄ¿Çåµ¥¡·£¬£¬£¬£¬£¬£¬£¬²¢ÒÑÍê³É¹«Ê¾¡£¡£¡£¡£¡£2121·Ç·²ÆìϺ¼ÖÝ2121·Ç·²Ò½Ñ§Ä¥Á·ÖÐÐÄÓÐÏÞ¹«Ë¾É걨µÄ¡°ÁÙ´²×¨²¡¸¨Öú¾öÒéϵͳÑз¢¼°Ó¦Ó᪡ªÑªÒºÖ×Áö¶àģ̬ÖÇÄܸ¨Öú¾öÒéϵͳÑз¢¼°Ó¦Óá±ÏîÄ¿ÀÖ³ÉÈëÑ¡£¬£¬£¬£¬£¬£¬£¬±ê¼Ç׏«Ë¾ÔÚѪҺÖ×Áö¾«×¼ÕïÁÆÁìÓòµÄÊýÖÇ»¯Êµ¼ùÔÙ»ñȨÍþÈϿɡ£¡£¡£¡£¡£

º¼ÖÝÊпÆÑ§ÊÖÒÕ¾Ö¹«Ê¾Ò³Ãæ½ØÍ¼
ÁÙ´²Ö®Í´£ºÑªÒºÖ×ÁöÕïÁÆÖØ´óÐÔ¸ß
ѪҺÖ×ÁöµÄÕïÁÆÍ¨³£Éæ¼°¶àÖÖÖØ´óµÄÕï¶ÏÊÖÒÕ£¬£¬£¬£¬£¬£¬£¬¼´MICM×ÛºÏÕï¶Ï£¬£¬£¬£¬£¬£¬£¬Æä°üÀ¨ÐÎ̬ѧ¼°Ï¸°û»¯Ñ§£¨Morphology£¬£¬£¬£¬£¬£¬£¬M£©¡¢ÃâÒßѧ£¨Iummunity£¬£¬£¬£¬£¬£¬£¬I£¬£¬£¬£¬£¬£¬£¬Á÷ʽϸ°ûÃâÒ߯ÊÎöºÍ/»ò²¡ÀíÃâÒß×éÖ¯»¯Ñ§£©¡¢È¾É«ÌåºËÐÍÆÊÎö£¨Cytogenetics£¬£¬£¬£¬£¬£¬£¬C£©¡¢·Ö×ÓÉúÎïѧÊÖÒÕ£¨Molecular£¬£¬£¬£¬£¬£¬£¬M£©¡£¡£¡£¡£¡£Í¨¹ý×ÛºÏÒÔÉÏÒªÁìµÄ¸÷×ÔÓÅÊÆ£¬£¬£¬£¬£¬£¬£¬Äܹ»Ô½·¢ÖÜÈ«¡¢×¼È·µØ¶ÔѪҺÖ×Áö¾ÙÐÐÕï¶Ï¡¢·ÖÐÍ¡¢Ô¤ºóÅжÏÒÔ¼°ÁÆÐ§¼à²â£¬£¬£¬£¬£¬£¬£¬´Ó¶ø¸üºÃµØÖ¸µ¼ÁÙ´²ÖÎÁÆ¡£¡£¡£¡£¡£
ÔÚÔçÆÚÕï¶Ï¡¢Ô¤ºóÕ¹Íû¡¢ÁÆÐ§¼à²âµÈ¶à¸ö»·½Ú£¬£¬£¬£¬£¬£¬£¬ÑªÒºÖ×ÁöµÄÕïÁÆ»¹±£´æ´ó×ÚÁÙ´²Í´µã¡£¡£¡£¡£¡£ºÃ±È£¬£¬£¬£¬£¬£¬£¬ÔÚÂýÐÔËèϵ°×Ѫ²¡£¡£¡£¡£¡£¨CML£©ÖУ¬£¬£¬£¬£¬£¬£¬²¿·ÖʹÓðÐÏòÒ©ÎïºóÈ¡µÃÓÅÒìÁÆÐ§µÄ»¼Õߣ¬£¬£¬£¬£¬£¬£¬¿ÉÒÔʵÏÖÍ£Ò©ºóµÄÎÞÖÎÁÆ»º½â£¬£¬£¬£¬£¬£¬£¬¶øÏÖÐÐÁÙ´²Ö¸ÄϺÍÏà¹ØÑо¿ÖÐÅú×¢Ö»ÓÐÔ¼50%µÄ»¼ÕßÄܹ»Í£Ò©Àֳɣ¬£¬£¬£¬£¬£¬£¬ÔõÑù¸ü¾«×¼µØÕÒµ½ÊʺÏÍ£Ò©µÄ»¼Õߣ¬£¬£¬£¬£¬£¬£¬³ÉΪ¼±Ðè½â¾öµÄÎÊÌâ¡£¡£¡£¡£¡£¼±ÐÔËèϵ°×Ѫ²¡£¡£¡£¡£¡£¨AML£©»¼ÕßÖÎÁƼƻ®µÄÖÆ¶©£¬£¬£¬£¬£¬£¬£¬Í¨³£ÐèÒª²Î¿¼¶àÖÖ¼ì²âÖ¸±ê£¬£¬£¬£¬£¬£¬£¬Õë¶Ô²î±ðΣº¦µÄ»¼ÕßΪҽÉúÌṩ¿ìËÙ¾öÒéÊý¾ÝÒÀ¾Ý£¬£¬£¬£¬£¬£¬£¬³ÉΪ°ü¹ÜÁÆÐ§µÄ»ù´¡¡£¡£¡£¡£¡£
Òò´Ë£¬£¬£¬£¬£¬£¬£¬ÎÞÂÛÊǽ«ÖØ´óÕï¶ÏÁ÷³Ì¾ÙÐÐ×Ô¶¯»¯Éý¼¶ÒÔÌáÉýЧÂÊ£¬£¬£¬£¬£¬£¬£¬ÕվɴÓÖØ´óµÄ¶àģ̬Êý¾ÝÖÐÕÒ³öÒªº¦µÄ¾öÒéµã£¬£¬£¬£¬£¬£¬£¬È˹¤ÖÇÄܶ¼Êǽâ¾öÏÖÓÐÁÙ´²ÎÊÌâµÄÒªº¦¡£¡£¡£¡£¡£
ÆÆ¾ÖÀûÆ÷£º AI¶àģ̬¾öÒéϵͳµÄÊÖÒÕÆÆ¾Ö
ÃæÁÙÖ×Áö°ÐÏòÖÎÁÆÍ£Ò©ºó¾Ó¸ß²»Ïµĸ´·¢Î£º¦¡¢¼±ÐÔ°×Ѫ²¡×ªË²¼´ÊŵĻƽð¾ÈÖÎʱ¼ä´°ÒÔ¼°¶à·¢ÐÔ¹ÇËèÁö£¨MM£©ÁÆÐ§ÆÀ¹À¶ÔÖØ¸´ÇÖÈëÐԹǴ©µÄ¸ß¶ÈÒÀÀµµÈؽ´ýÍ»ÆÆµÄÁÙ´²Äæ¾³£¬£¬£¬£¬£¬£¬£¬2121·Ç·²×¤×ãÁÙ´²ÐèÇ󣬣¬£¬£¬£¬£¬£¬¿ªÕ¹¡°ÑªÒºÖ×Áö¶àģ̬ÖÇÄܸ¨Öú¾öÒéϵͳÑз¢¼°Ó¦Óá±ÏîÄ¿¡£¡£¡£¡£¡£
¸ÃÏîÄ¿½«ÖÂÁ¦ÓÚÉî¶ÈÕûºÏ°üÀ¨ÕæÊµÌìÏÂÓÃÒ©Êý¾Ý¡¢¶à×éѧ·Ö×Ó·ÖÐÍ¡¢¶¯Ì¬Ó°ÏñѧÐÅÏ¢¼°»¼ÕßÈ«²¡³Ì¹ÜÀí¼Í¼ÔÚÄڵĺ£Á¿¶àά¶ÈÊý¾Ý£¬£¬£¬£¬£¬£¬£¬²¢ÔËÓÃÇ°ÑØÈ˹¤ÖÇÄÜÊÖÒÕ£¨AI£©¾ÙÐÐÖÇÄÜÆÊÎöÓëÉî¶ÈÍÚ¾ò£¬£¬£¬£¬£¬£¬£¬Ö¼ÔÚ¹¹½¨Ò»Ì×Í»ÆÆÐÔµÄÁÙ´²¾öÒéÖ§³Öϵͳ£¬£¬£¬£¬£¬£¬£¬ÎªÕâЩÑÏËàÌôÕ½Ìṩ¾«×¼¡¢¸ßЧÇÒ·ÇÇÖÈëÐÔµÄÁ¢Òì½â¾ö¼Æ»®¡ª¡ª
1. CML¡°Í£Ò©ÖúÊÖ¡±¡ª¡ªÈÃTKIÇå¾²¼õÁ¿³ÉΪ¿ÉÄÜ
°ÐÏòÒ©£¨TKI£©ËäÓÐÓ㬣¬£¬£¬£¬£¬£¬µ«ºã¾Ã·þÓÃ»á¸ø»¼Õß´øÀ´¸±×÷Óú;¼Ã¼ç¸º¡£¡£¡£¡£¡£Ïà¹ØÑо¿ÏÔʾ£¬£¬£¬£¬£¬£¬£¬Ô¼50%µÖ´ïÉî¶È»º½â£¨DMR£©²¢ÊµÑéÍ£Ò©µÄ»¼Õ߻Ḵ·¢¡¾1¡¿¡£¡£¡£¡£¡£±¾ÏîÄ¿½«Í»ÆÆ½öÒÀÀµ·Ö×Ó»º½âʱ³¤µÄ¾ÖÏÞ£¬£¬£¬£¬£¬£¬£¬Á¢ÒìÐÔµØÕûºÏ¹ÇËèͿƬ¡¢¶à²ÎÊýÁ÷ʽ£¨¼à²âÃâÒß״̬ÈçNKϸ°û¡¢ºÄ½ßTϸ°û£©¡¢Ï¸°ûÒò×ӵȡ°ÃâÒß×éѧ¡±Êý¾Ý£¬£¬£¬£¬£¬£¬£¬¹¹½¨AIÕ¹ÍûÄ£×Ó£¬£¬£¬£¬£¬£¬£¬Îª»¼ÕßÊä³ö¸öÐÔ»¯µÄ¡°Í£Ò©/¼õÒ©ÀֳɸÅÂÊ¡±ºÍ¸´·¢Î£º¦ÆÀ¹À£¬£¬£¬£¬£¬£¬£¬ÈÃÇ徲ͣҩ³ÉΪ¿ÉÄÜ¡£¡£¡£¡£¡£
2. AML¡°7Ìì¼Æ»®ÍƼöÆ÷¡±¡ª¡ª½ô×¥ÖÎÁÆ»Æ½ð´°¿ÚÆÚ
AMLÏ£ÍûѸÃÍ£¬£¬£¬£¬£¬£¬£¬ÖÎÁÆ´°¿ÚÆÚ¶Ì¡£¡£¡£¡£¡£»£»£»£»£»£»£»£»ùÒò¼ì²âµÄÆÚ´ýʱ¼ä³ÉΪÕïÁÆÖÐµÄÆ¿¾±¡£¡£¡£¡£¡£±¾ÏîÄ¿½«Ñз¢¹ÇËèͿƬÃë¼¶¶àģ̬ÆÊÎöÊÖÒÕ£¬£¬£¬£¬£¬£¬£¬Ê¹ÓÃAIÖ±½Ó´ÓͿƬͼÏñÖÐʵʱ¶¨Î»ÈçFLT3-ITD¡¢NPM1µÈÒªº¦Çý¶¯Í»±ä£¬£¬£¬£¬£¬£¬£¬ÔÚ»¼Õß¾ÙÐл¯ÁÆ»ò¾ÙÐаÐÏòÓÃÒ©7ÌìÄÚÊä³öÓÐÓÃÐÔ¸ÅÂʺÍ×¥ÊÖÐÔÍ»±äÒ©ÎïÆ¥Å佨Òé¡£¡£¡£¡£¡£ºóÐøÔÙÍŽáÁ÷ʽÃâÒß·ÖÐͺͻùÒò²âÐòÊý¾Ý£¬£¬£¬£¬£¬£¬£¬¶¯Ì¬Ð£×¼Î£º¦·Ö²ãºÍÒ©ÎïÆ¥Å䣬£¬£¬£¬£¬£¬£¬ÏÔÖøËõ¶ÌÖÎÁƿմ°ÆÚ£¬£¬£¬£¬£¬£¬£¬ÌáÉýÉúÑÄÂÊ¡£¡£¡£¡£¡£
3.MM¡°ÎÞ´´AI-MRD¼à²â¡±¡ª¡ªÍâÖÜÑªÌæ»»¹ÇËè´©´Ì
ÖØ¸´¹ÇËè´©´ÌÊÇMM»¼Õ߯À¹ÀÁÆÐ§ºÍ¸´·¢µÄÖ÷Ҫʹ¿àȪԴ¡£¡£¡£¡£¡£±¾ÏîÄ¿½«¹¹½¨»ùÓÚÍâÖÜѪµÄÖÇÄÜMRDÆÀ¹Àϵͳ£¬£¬£¬£¬£¬£¬£¬Í¨¹ýAIÈÚºÏÍâÖÜѪÁ÷ʽ£¨Ñ»·½¬Ï¸°û£©¡¢¶¨Á¿M-ÂѰ×ÖÊÆ×¡¢ÓÎÀëÖ×ÁöDNA(ctDNA)µÈ¶àģ̬¶¯Ì¬Êý¾Ý£¬£¬£¬£¬£¬£¬£¬Êä³ö¿ÉÚ¹Ê͵ġ°AI-MRD¸ÅÂÊ·ÖÖµ¡±£¬£¬£¬£¬£¬£¬£¬ÊµÏ֏߯µ¡¢ÎÞ´´¡¢È«¾°µÄ²ÐÁôÁö¸ººÉ¼à²â¡£¡£¡£¡£¡£Õâ²»µ«ÄܼõÇỼÕßÍ´¿à£¬£¬£¬£¬£¬£¬£¬¸üÄÜÔçÆÚʶ±ð¸ß¸´·¢Î£º¦£¬£¬£¬£¬£¬£¬£¬Ö¸µ¼Î¬³ÖÖÎÁƵ÷½â¡£¡£¡£¡£¡£
Éç»á¼ÛÖµ£º´Ó¾«×¼Ò½ÁƵ½Íƶ¯ÎÀÉú¾¼Ãѧ¸ïÃü
ѪҺÖ×Áöºã¾Ãλ¾Ó¶ñÐÔÖ×ÁöÖÂËÀÂÊǰÏߣ¬£¬£¬£¬£¬£¬£¬Æä¶ñ»¯¿ì¡¢Ò׸´·¢¡¢ÕïÁÆÓöȸߡ£¡£¡£¡£¡£ÒÆÖ²¡¢°ÐÏòÒ©¡¢CAR-TËä°ÑÉúÑÄÏ£ÍûÍùÇ°ÍÆÁËÒ»´ó²½£¬£¬£¬£¬£¬£¬£¬µ«¶¯éü¼¸Ê®ÍòÒÔÖÂÉϰÙÍòµÄÆÆ·Ñ£¬£¬£¬£¬£¬£¬£¬ÈÃÎÞÊý¼ÒÍ¥¡°¿´µÃ¼ûÏ£Íû£¬£¬£¬£¬£¬£¬£¬¹»²»×ÅÒ©¡±¡£¡£¡£¡£¡£
±¾ÏîÄ¿Ñз¢µÄ¶àģ̬AIѪҺÖ×Áö¾öÒéϵͳ£¬£¬£¬£¬£¬£¬£¬¾ÍÊÇΪÁËÍÆ¶¯¼â¶ËÖÎÁÆÆ½¼Û¿É¼°¡£¡£¡£¡£¡£Ëü½«°ÑÔ±¾ÐèÒªÊýСʱµÄÖØ´ó¼ì²âѹËõµ½¡°Ãë¼¶¡±£¬£¬£¬£¬£¬£¬£¬ÈÃÂÄÀúÓÃÒ©Éý¼¶Îª¡°Ç§ÈËǧ·½¡±¡£¡£¡£¡£¡£»£»£»£»£»£»£»£»ùÓÚÿλ»¼ÕßÁ¿Éí¶¨ÖÆµÄÔ¤·À¡¢Õï¶Ï¡¢ÖÎÁÆÒ»Ì廯¼Æ»®£¬£¬£¬£¬£¬£¬£¬¼È¾«×¼ÓÖʡǮ£¬£¬£¬£¬£¬£¬£¬ÖÜÈ«Â䵨ºóÔ¤¼Æ¿ÉΪº£ÄÚÒ½±£ºÍ»¼Õß¼ÒÍ¥½ÚÔ¼ÉÏÒÚÔªÖ§³ö£¬£¬£¬£¬£¬£¬£¬Èþ«×¼Ò½ÁÆÕæÕý×ß½øÑ°³£ÀèÃñ¼Ò¡£¡£¡£¡£¡£
µ±ÑªÒºÖ×ÁöÓö¼û¶àģ̬AI£¬£¬£¬£¬£¬£¬£¬ÎÒÃÇÕý¼ûÖ¤Ò»³¡ÕïÁÆ·¶Ê½µÄÖØ¹¹£º¸üÔçµÄ¸ÉÔ¤¡¢¸ü×¼µÄ¾öÒé¡¢¸üÇáµÄÍ´¿à¡£¡£¡£¡£¡£ÏîÄ¿Ñз¢Àú³ÌÖУ¬£¬£¬£¬£¬£¬£¬2121·Ç·²»¹½«ÍŽáÉϺ£½»Í¨´óѧҽѧԺÁ¥ÊôÈð½ðÒ½Ôº¡¢»ªÖпƼ¼´óѧͬ¼ÃҽѧԺÁ¥ÊôкÍÒ½Ôº¡¢ÎÂÖÝÒ½¿Æ´óѧÁ¥ÊôµÚÒ»Ò½ÔºµÈ¶à¼ÒÍ·²¿Èý¼×Ò½Ôº£¬£¬£¬£¬£¬£¬£¬¿ªÕ¹Ç°Õ°ÐÔ±ÈÕÕÑо¿£¬£¬£¬£¬£¬£¬£¬È·±£Ëã·¨¿ÉÚ¹ÊÍ¡¢¿ÉÂ䵨¡£¡£¡£¡£¡£
½ô¸ú¡°¿µ½¡Öйú¡±¡°Êý×ÖÖйú¡±¹ú¼ÒÕ½ÂÔ°²ÅÅ£¬£¬£¬£¬£¬£¬£¬2121·Ç·²½«Ãª¶¨¡°Ò½Ñ§Õï¶ÏÖÇÄܽâ¾ö¼Æ»®ÒýÁìÕß¡±µÄÕ½ÂÔ¶¨Î»£¬£¬£¬£¬£¬£¬£¬Ò»Á¬Éî¸ûÒ½ÁÆ¿µ½¡³¡¾°£¬£¬£¬£¬£¬£¬£¬ÒÔ¡°AI+Êý¾Ý¡±ÎªÒýÇæ£¬£¬£¬£¬£¬£¬£¬ÒÔ½¹µã×ÔÑÐÊÖÒÕΪÇý¶¯Á¦£¬£¬£¬£¬£¬£¬£¬Ò»Ö±ÌáÉýÕïÁƾ«×¼¶È¡¢Á¢Ò쿵½¡¹ÜÀíģʽ£¬£¬£¬£¬£¬£¬£¬ÒýÁ칤ҵÉú̬ÖÇÄÜ»¯Î´À´¡£¡£¡£¡£¡£
²Î¿¼ÎÄÏ×£º
1. Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747-757.